Leap Therapeutics Reports Clinical Update and 2018 Financial Results
CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported an update on its clinical development programs along with financial results for the fourth quarter and year ended December 31, 2018.
Leap Highlights
-- DKN-01 plus Keytruda® exceeds benchmarks in gastric cancer
-- Predictive biomarker enables patient selection
-- DKN-01 plus paclitaxel exceeds benchmarks in esophagogastric cancer
-- Two DKN-01 monotherapy responses in endometrial cancer
-- DKK1-positive prostate cancer study enrolling 97 patients
-- TRX518 has first reported GITR agonist monotherapy confirmed partial
response in the industry
-- TRX518 combination with Keytruda or Opdivo® demonstrating durable
complete and partial responses
-- TRX518 combination with gemcitabine achieved partial response and
meaningful clinical benefit in patients who had previously progressed on
gemcitabine therapy
-- Raised $13.225 million to support further clinical development
DKN-01 Clinical Update
DKN-01 is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01, as a single agent, has achieved partial responses in three different cancer indications. In combination with immune checkpoint inhibitors and with chemotherapy, DKN-01 has achieved overall response rates and survival data that is greater than the historical benchmarks, particularly in biomarker targeted patient populations.
-- DKN-01 plus Keytruda (pembrolizumab) exceeds PD-1 antibody monotherapy
benchmarks in gastric and gastroesophageal junction cancer Leap has
completed the enrollment of fifty-two patients who have advanced
esophagogastric cancer and who were naïve to PD-1/PD-L1 therapy.
Thirty-four patients with gastric (GC) or gastroesophageal junction
(GEJ) cancer were enrolled, and twenty-five are evaluable for tumor
response. Five patients (20%) have had a partial response (PR) by
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and eight
patients (32%) have experienced a best response of stable disease (SD),
representing a disease control rate (DCR) of 52%. One patient continuing
on therapy for six months has 36.4% tumor reduction, a PR by immune
related RECIST (iRECIST), but not considered a PR by RECIST v1.1 due to
tumor growth of greater than 20% at the first assessment, likely
representing pseudoprogression. All of the patients in the study have
tumors that are microsatellite stable or unknown, representing a
population in which the benchmark overall response rate (ORR) of PD-1
antibodies is approximately 9%.
-- DKK1 biomarker predicts response to DKN-01 plus Keytruda The overall
response rate (ORR) and DCR has been higher in patients with higher DKK1
expression as measured by in situ hybridization RNAscope (H-scores).
DKK-1 H-scores have been determined for thirty-two evaluable PD-1
therapy naïve patients, including nineteen GC/GEJ patients. Nine GC/GEJ
patients had DKK1 H-Scores of greater than 31, including the six PRs
(66.7%) by RECIST and iRECIST, two patients (22.2%) experiencing SD, and
one patient (11.1%) with progressive disease. In the ten GC/GEJ patients
with DKK1 H-Scores of 31 or lower, two patients (20%) had a best
response of SD and eight patients (80%) had progressive disease.
-- DKN-01 plus paclitaxel exceeds chemotherapy benchmark in esophagogastric
cancer patients In total, fifty-eight patients with advanced
esophagogastric cancer were treated, with fifty-two evaluable for
response. Across all lines of prior therapy and tumor types, DKN-01 plus
paclitaxel generated a 25.0% ORR, 13.4 weeks median progression-free
survival (PFS), and 27.9 weeks median overall survival (OS). In the
fifteen evaluable second-line patients, the combination of DKN-01 plus
paclitaxel generated a 46.7% ORR, 19.6 weeks PFS, and 61.1 weeks OS. In
a recent benchmark study in second-line esophageal cancer patients,
single agent chemotherapy achieved a 6.7% ORR, 3.4 month PFS, and 7.1
month OS.
-- Two monotherapy and one combination therapy responses for DKN-01 in
advanced gynecological cancers, with seventy-eight patients now enrolled
DKN-01, both as a monotherapy and in combination with paclitaxel,
generated PRs and durable clinical benefit, including in patients with
carcinosarcoma and Wnt pathway alterations. There have now been two
DKN-01 monotherapy PRs and one PR in combination with paclitaxel in
patients with epithelial endometrial cancer, all of whom have had Wnt
pathway alterations. In total, seventy-eight patients have now been
enrolled in this study, and many are pending first efficacy evaluation.
-- Investigator-Initiated Study in DKK1-positive prostate cancer underway
DKK1 is upregulated in a large number of patients whose advanced
prostate cancer tumors do not express the androgen receptor. A study led
by NYU Langone Medical Center and funded by Leap is enrolling metastatic
DKK1-positive castration-resistant prostate cancer patients who have
progressed on one or more androgen receptor therapies to be treated with
either DKN-01 monotherapy or DKN-01 in combination with docetaxel.
TRX518 Clinical Update
TRX518 is unique among Glucocorticoid-Induced TNF Receptor (GITR) agonist antibodies for its aglycosyl design, permitting activation of GITR signaling without depleting CD8-positive T-effector cells. TRX518 has been shown to increase CD8-positive T-effector cell infiltrate and the expression of granzyme B, as well as decrease CD4-positive T-regulatory cell infiltrate. TRX518 is the first GITR agonist antibody in the industry to have reported partial responses as a monotherapy, in combination with PD-1 antibodies, and in combination with gemcitabine chemotherapy.
-- Monotherapy patient with partial response A non-virally mediated
hepatocellular cancer patient, who has been treated with single agent
TRX518 for nearly two years, has achieved a confirmed PR with 47% tumor
reduction and continues on study. TRX518 has demonstrated safety,
tolerability, and clinical benefit as a monotherapy in patients with
heavily pretreated solid tumors.
-- Combination with Keytruda or Opdivo (nivolumab) achieved durable,
confirmed complete and partial responses in patients not expected to
respond to anti-PD-1 therapy An esophageal squamous cell carcinoma
patient has a confirmed complete response. The patient has been treated
for ten months and continues on study. A patient with uveal melanoma
achieved 23% tumor reduction and six months of SD. A patient with
urothelial carcinoma who had failed prior Keytruda had a confirmed PR
and remained on therapy for six months. Twelve patients have recently
enrolled in the expansion cohort for the Keytruda combination.
-- Combination with gemcitabine achieved partial response and meaningful
clinical benefit in patients who had progressed on gemcitabine therapy A
pancreatic cancer patient, who had previously progressed on gemcitabine
therapy and two other prior lines of therapy, has now achieved a
confirmed PR with 58% tumor reduction. The patient has been treated for
nine months and continues on study.
Selected Year-End and Fourth Quarter 2018 Financial Results
Net loss was $23.1 million for the year ended December 31, 2018, compared to $29.7 million for the year ended December 31, 2017. This decrease was primarily due to a noncash charge to decrease the fair value of the warrant liability. Net income was $1.5 million for the fourth quarter of 2018, compared to a net loss of $6.6 million for the same period in 2017. The 2018 increase was due to the decrease in the fair value of the warrant liability in the fourth quarter, leading to a $11 million non-cash gain. The requirement to revalue the warrant liability each quarter has resulted in the Company's net income or net loss being highly variable.
Research and development expenses were $21.8 million for the full year 2018, compared to $22.5 million for the same period in 2017. This decrease was primarily due to reduced manufacturing expenses of our clinical product candidates and a decrease in stock based compensation expense offset by increased clinical trial costs due to increased patient enrollment. Research and development expenses were $6.9 million for the fourth quarter of 2018, compared to $4.4 million for the same period in 2017. This increase was due to increased clinical development expense associated with the start-up operations and enrollment of our ongoing clinical trials.
General and administrative expenses were $8.9 million for the full year 2018, compared to $9.8 million for the same period in 2017. This decrease was due to a decrease in stock based compensation expense. General and administrative expenses were $2.1 million for the fourth quarter of 2017, compared to $2.1 million for the same period in 2017.
Cash, cash equivalents and marketable securities totaled $16.3 million at December 31, 2018. Research and development incentive receivables totaled $0.8 million. Subsequent to the financial year end, Leap completed a public offering of $13.225 million of common stock and warrants, resulting in net cash proceeds of $12.1 million. Leap believes that its current cash and the expected receipt of research and development tax incentives will be sufficient to fund its operating expenses into the second quarter of 2020.
About Leap Therapeutics
Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include statements regarding Leap's expectations with respect to the development and advancement of DKN-01, TRX518, and other programs, including the initiation, timing and design of future studies, enrollment in future studies, business development, and other future expectations, plans and prospects. Leap has attempted to identify forward looking statements by such terminology as ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the ability to complete a financing or form business development relationships to fund our expenses; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics' periodic filings with the SEC, including Leap Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2018 that Leap filed with the SEC on April 1, 2019. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
KEYTRUDA(®) is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. OPDIVO® is a registered trademark of Bristol Myers-Squibb Company.
CONTACT:
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Argot Partners
Investor Relations
Heather Savelle
212-600-1902
heather@argotpartners.com
Leap Therapeutics, Inc.
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(Unaudited)
Year Ended December 31 Three Months Ended December 31
2018 2017 2018 2017
Operating expenses:
Research and development $21,830 $22,503 $6,908 $4,416
General and administrative 8,921 9,849 2,063 2,130
Total operating expenses 30,751 32,352 8,971 6,546
Loss from operations (30,751) (32,352) (8,971) (6,546)
Interest income 447 170 120 40
Interest expense (19) (528) (1) (516)
Interest expense - related party (121)
Australian research and development incentives 756 1,715 (432) (137)
Foreign currency gains (loss) (835) 759 (220) (64)
Change in fair value of warrant liability 7,284 473 11,004 473
Loss before income taxes (23,118) (29,884) 1,500 (6,750)
Income taxes (20) 157 (20) 157
Net loss (23,138) (29,727) 1,480 (6,593)
Accretion of preferred stock to redemption value (244)
Net loss attributable to common stockholders $(23,138) $(29,971) $1,480 $(6,593)
Net income (loss) per share
Basic $(1.64) $(3.27)
Diluted $(2.11) $(3.31)
Weighted average common shares outstanding
Basic 14,144,287 9,161,844
Diluted 14,412,695 9,188,587
Leap Therapeutics, Inc.
Consolidated Balance Sheets
(in thousands, except share and per
share amounts)
December 31,
2018 2017
Assets
Current assets:
Cash and cash equivalents $16,284 $25,737
Research and development incentive receivable 836 1,744
Prepaid expenses and other current assets 202 177
Total current assets 17,322 27,658
Property and equipment, net 86 135
Deferred tax asset 124 158
Other assets 1,542 1,111
Total assets $19,074 $29,062
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $3,579 $2,622
Accrued expenses 2,872 3,461
Total current liabilities 6,451 6,083
Non current liabilities:
Warrant liability 3,448 11,862
Total liabilities 9,899 17,945
Stockholders' equity:
Common stock, $0.001 par value;
100,000,000 shares authorized as 15 12
of December 31, 2018 and 2017,
14,703,159 and 12,354,014 shares
issued
and outstanding as of December
31, 2018 and December 31, 2017,
respectively
Additional paid-in capital 162,393 141,770
Accumulated other comprehensive
income (loss) 302 (268)
Accumulated deficit (153,535) (130,397)
Total stockholders' equity 9,175 11,117
Total liabilities and
stockholders' equity $19,074 $29,062
Leap Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
Year Ended December 31, Three Months Ended December 31,
2018 2017 2018 2017
Cash used in operating activities $(26,033) $(22,137) $(7,050) $(6,369)
Cash used in investing activities (64)
Cash provided by (used in) financing activities 15,906 47,763 (40) 17,895
Effect of exchange rate changes on cash and cash equivalents 674 (618) 125 8
Net increase (decrease) in cash and cash equivalents (9,453) 24,944 (6,965) 11,534
Cash and cash equivalents at beginning of period 25,737 793 23,249 14,203
Cash and cash equivalents at end of period $16,284 $25,737 $16,284 $25,737
View original content to download multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-reports-clinical-update-and-2018-financial-results-300821703.html
SOURCE Leap Therapeutics, Inc.
